EDIT — Editas Medicine, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1650664 ·
Last close
$3.08
Market Cap
$301.55M
52W High
$3.65
52W Low
$1.82
ADV30
1,570,973
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,831,000 | — | -25,003,000 | -24,982,000 | 149,338,000 | 123,648,000 | 144,930,000 |
| Dec 2025 | 24,741,000 | — | -14,016,000 | -5,620,000 | 186,534,000 | 146,645,000 | 159,246,000 |
| Sep 2025 | 7,543,000 | — | -24,548,000 | -25,117,000 | 201,751,000 | 165,648,000 | 188,298,000 |
| Jun 2025 | 3,578,000 | — | -25,462,000 | -53,235,000 | 210,581,000 | 138,542,000 | 191,392,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-165,241,000
Investing CF
$138,668,000
Financing CF
$40,470,000
CapEx
$-1,147,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.89
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,628,503,000
Inventory
—
Receivables
$15,176,000
ST Investments
$0
EBIT TTM
$-153,889,000
Pretax Income TTM
$-160,060,000
Interest Exp TTM
$6,171,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$38,693,000
EBITDA
$-85,186,000
Free Cash Flow
$-73,816,000
Enterprise Value
$195,200,352
Total Cash
$123,648,000
Total Debt
$17,297,000
Shares Out
97,906,282
Trailing EPS
$-1.14
Book Value
$0.04
ROE
-326.1%
ROA
-26.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 40,520,000 | -99,336,000 | -160,060,000 | 186,534,000 | 159,246,000 | — | -165,241,000 |
| Dec 2024 | 32,314,000 | -238,920,000 | -237,093,000 | 341,589,000 | 207,315,000 | — | -210,284,000 |
| Dec 2023 | 78,123,000 | -169,181,000 | -153,219,000 | 499,153,000 | 150,056,000 | — | -132,178,000 |
| Dec 2022 | 19,712,000 | -225,950,000 | -220,432,000 | 514,321,000 | 153,641,000 | — | -177,349,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$5,439,000
NetIncome TTM
$-162,886,000
OpCashFlow TTM
$0
Assets (Latest)
$341,589,000
Forward EPS
$-0.93
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARMP | Armata Pharmaceuticals, Inc. | $299.93M | $8.17 | — |
| SRZN | Surrozen, Inc./DE | $303.84M | $26.17 | — |
| SABS | SAB Biotherapeutics, Inc. | $291.33M | $3.81 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $321.59M | $1.29 | — |
| IVVD | Invivyd, Inc. | $324.07M | $1.10 | — |
News headlines (Yahoo Finance, 1h cache)
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
2026-05-26 13:05 · Yahoo
Editas Medicine Announces Proposed Public Offering
2026-05-26 10:15 · Yahoo
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
2026-05-26 10:01 · Yahoo
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate,
2026-05-21 17:30 · Yahoo
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
2026-05-14 10:01 · Yahoo
Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates
2026-05-11 13:35 · Yahoo
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
2026-05-06 15:57 · Yahoo
Company News for May 6, 2026
2026-05-06 13:39 · Yahoo
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
2026-05-05 12:25 · Yahoo
Editas Medicine Announces First Quarter 2026 Results and Business Updates
2026-05-05 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.